Best Biotechnology and Pharmaceutical Investing Interviews of 2012: Opportunities in Oncology Treatments Create Stock Market Winners
67 WALL STREET, New York - November 28, 2012 - The Wall Street Transcript has just published its Best Biotechnology and Pharmaceutical Investing Interviews of 2012 offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Biotechnology and Pharmaceutical Investing
Companies include: Amgen Inc. (AMGN), Celgene Corporation (CELG), Celldex Therapeutics, Inc. (CLDX), Gilead Sciences (GILD), and many others.
In the following excerpt from the Best Biotechnology and Pharmaceutical Investing Interviews of 2012, an expert analyst discusses the outlook for the sector for investors:
TWST: What are some of the most exciting or promising new drugs, treatments or technologies coming out of your companies right now that investors should be aware of?
Mr. Peaker: The oncology space is actually very rapidly evolving, so let's start with oncology first - I think that will be interesting. So oncology, and sometimes I guess in the same field people include immunology, is certainly a rapidly evolving space, where new data is presented quite frequently, and studies often don't take a very long period of time compared to some other indications, like figuring cholesterol and things like that.
So in the oncology space, some of the interesting new developments are Celldex (CLDX) as a new drug in breast cancer, which is targeting a completely novel target, which is certainly exciting with some of the early stages of development, but the initial data is very encouraging. Speaking of breast cancer, ImmunoGen (IMGN) with their partner Roche (ROG.VX) - I don't cover Roche, I cover ImmunoGen, but I follow certainly this space. Also, it's a very interesting breast cancer drug that shows very, very promising data. Furthermore, in cancer, Curis (CRIS) with its partner Genentech, recently launched a basal cell carcinoma drug, which is very exciting, and while it still needs a little time to figure out how to best use it, the efficacy is very, very encouraging.
On the cell therapy space, which is another area that I cover, there is a company...
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
